springworks - Search News

News

Merck KGaA to Buy US Drugmaker Springworks

Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in the country.

Reuters on MSN · 18h

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

Yahoo Finance · 20h

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The acquisition price translates to an equity value of around $3.

Fierce Pharma21h

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

TMCnet21h

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join our ...

14h

Stamford-based drug developer for rare cancers and tumors sold for $3.9 billion to German company

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Fierce Pharma4d

Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

SpringWorks expects CHMP of EMA will adopt MAA opinion on nirogacestat in Q2

SpringWorks Therapeutics (SWTX) announced that the Company anticipates the Committee for Medicinal Products for Human Use, CHMP, of the ...

Devdiscourse1d

Global Health Updates: From Mergers to Measles and Medicine

The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results